Bioequivalence and Bioavailability
Bioavailability describes the rate and extent to which a drug substance is absorbed and becomes available at its site of action; bioequivalence compares that bioavailability between a test product and a reference product to establish they can be expected to have the same clinical effect. Bioequivalence data, rather than a repeat of the reference product’s full clinical efficacy program, is what typically supports approval of a generic or a reformulated product.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 22 LINKSBioequivalence converts a manufacturing claim into a pharmacokinetic one: the study establishes that a formulation performs the same in the body, so any change made afterwards has to answer to it.
06 · QUALITY MATURITY — BIOEQUIVALENCE AND BIOAVAILABILITY, REACTIVE TO ADAPTIVE
The study is treated as a regulatory hurdle. The batch used to demonstrate equivalence has no special standing afterwards.
The study is well conducted and the biobatch is identified, but the link between that batch and routine commercial manufacture is not maintained.
The biobatch is a documented reference point: its process, its dissolution profile and its composition are the baseline every later change is assessed against.
Post-approval changes are screened against that baseline before they are made, with a defined rule for when in-vitro comparison suffices and when it does not.
Formulation and process are designed so in-vitro performance reliably tracks in-vivo behaviour, and the biowaiver argument is built rather than hoped for.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 2 regulatory bodies: FDA, ICH.
RECORDS & OBJECTIVE EVIDENCE
- The study protocol and report, with the statistical approach pre-specified
- Biobatch manufacturing records, composition and dissolution profile
- Bioanalytical method validation for the analyte and matrix used
- The comparison between biobatch and commercial-scale process, with any differences assessed
- Post-approval change assessments referring back to the batch that established equivalence
COMMON INSPECTION FINDINGS
- A biobatch manufactured by a process materially different from commercial manufacture, with no bridging assessment
- Post-approval formulation or process changes made without reference to the equivalence established
- Bioanalytical method validation not covering the concentration range the study actually produced
- Statistical approach or population selection altered after the data was seen
- A biowaiver claimed on solubility and permeability grounds the dossier does not demonstrate
What Bioavailability and Bioequivalence Actually Measure
Bioavailability is characterized primarily through plasma concentration over time following dosing, summarized by pharmacokinetic parameters such as peak concentration (Cmax) and total exposure (area under the curve, AUC). Bioequivalence is established when a test and reference product’s Cmax and AUC fall within a predefined statistical acceptance range of one another, most commonly a 90% confidence interval within 80–125% of the reference — narrow enough that a clinically meaningful difference is very unlikely to be missed.
Study Design Considerations
Most bioequivalence studies use a crossover design, where the same subjects receive both test and reference product in randomized sequence, which controls for between-subject variability far more efficiently than a parallel-group design. Fasting and fed-state studies may both be required where food is known to affect absorption, and highly variable drugs — those with unusually large intrinsic pharmacokinetic variability — may need specialized statistical approaches or wider, variability-adjusted acceptance criteria to avoid unnecessarily large sample sizes.
The Biopharmaceutics Classification System and Biowaivers
For certain highly soluble, highly permeable drug substances, and under defined conditions, in-vivo bioequivalence testing can sometimes be waived in favor of in-vitro dissolution comparison alone — a Biopharmaceutics Classification System (BCS)-based biowaiver. This is only available where the underlying scientific rationale and dissolution behavior genuinely support that dissolution is an adequate surrogate for absorption in that specific case.
Where BA/BE Fits Into Regulatory Approval
For generic products, a demonstrated bioequivalence package substitutes for repeating the reference product’s full nonclinical and clinical safety and efficacy program, on the scientific premise that equivalent systemic exposure produces equivalent therapeutic effect. This is the foundational logic underlying abbreviated approval pathways in essentially every major regulatory jurisdiction.
FREQUENTLY ASKED
What is the standard acceptance range for bioequivalence?
Most commonly, a 90% confidence interval for the test-to-reference ratio of Cmax and AUC falling within 80–125%, though specialized approaches exist for highly variable drugs and narrow therapeutic index products.
Why do most bioequivalence studies use a crossover design?
Because the same subjects serve as their own control across both treatments, a crossover design removes between-subject variability from the comparison, generally requiring fewer subjects than a parallel-group design would to reach the same statistical confidence.
Can dissolution testing ever replace a bioequivalence study?
Yes, in defined circumstances — a BCS-based biowaiver can allow in-vitro dissolution comparison to substitute for an in-vivo study, but only where the drug substance’s solubility and permeability characteristics, and the product’s dissolution behavior, meet the specific conditions that justify the waiver.
Is bioequivalence the same thing as therapeutic equivalence?
Bioequivalence is the pharmacokinetic evidence typically relied upon to infer therapeutic equivalence; the two terms are closely related but not strictly identical, and some jurisdictions apply additional criteria before formally designating therapeutic equivalence.